Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sino Biopharmaceutical ( (HK:1177) ) just unveiled an announcement.
Sino Biopharmaceutical reported a significant financial performance for the first half of 2025, with a 10.7% increase in revenue to RMB 17.57 billion and a 140.2% rise in profit attributable to owners from continuing operations. This growth was driven by increased sales of innovative products and higher dividend income. The company’s strategic focus on innovative therapies and its robust market presence continue to strengthen its position in the pharmaceutical industry.
The most recent analyst rating on (HK:1177) stock is a Buy with a HK$6.19 price target. To see the full list of analyst forecasts on Sino Biopharmaceutical stock, see the HK:1177 Stock Forecast page.
More about Sino Biopharmaceutical
Sino Biopharmaceutical Limited is a leading pharmaceutical conglomerate in China, known for its innovative R&D-driven approach. The company has a fully-integrated industrial chain that includes various R&D platforms, intelligent production operations, and a strong sales system. Its product range includes biopharmaceutical and chemical medicines, focusing on therapeutic areas such as oncology, liver/metabolic diseases, respiratory, and surgery/analgesia. Listed on the Hong Kong Stock Exchange since 2000, Sino Biopharm has been recognized as one of the ‘Top 50 Global Pharmaceutical Enterprises’ and ‘Asia’s Fab 50 Companies.’
YTD Price Performance: 146.22%
Average Trading Volume: 175,820,071
Technical Sentiment Signal: Buy
Current Market Cap: HK$139.9B
For detailed information about 1177 stock, go to TipRanks’ Stock Analysis page.